Insider Transactions in Q4 2021 at Aura Biosciences, Inc. (AURA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2021
|
Matrix Capital Management Company, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,785,000
+30.27%
|
$24,990,000
$14.0 P/Share
|
|
Nov 02
2021
|
Matrix Capital Management Company, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,327,870
+50.0%
|
-
|
|
Nov 02
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
710,000
+18.93%
|
$9,940,000
$14.0 P/Share
|
|
Nov 02
2021
|
Medicxi Ventures Management (Jersey) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,329,892
+50.0%
|
-
|
|
Nov 02
2021
|
David Michael Johnson |
BUY
Conversion of derivative security
|
Indirect |
139,672
+50.0%
|
-
|
|
Nov 02
2021
|
Pinos Elisabet De Los |
BUY
Conversion of derivative security
|
Indirect |
4,552
+3.35%
|
-
|
|
Oct 28
2021
|
Christopher Brett Primiano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+50.0%
|
-
|
|
Oct 28
2021
|
Julie B Feder Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+50.0%
|
-
|
|
Oct 28
2021
|
Mark De Rosch Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+50.0%
|
-
|
|
Oct 28
2021
|
Pinos Elisabet De Los |
BUY
Grant, award, or other acquisition
|
Direct |
74,357
+50.0%
|
-
|
|
Oct 28
2021
|
Cadmus Rich Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+50.0%
|
-
|